<DOC>
	<DOC>NCT01416311</DOC>
	<brief_summary>To investigate safety and efficacy in the actual use of REVOLADE collected from all subjects receiving the drug until data from a specified number of subjects are accumulated to identify factors considered to influence its safety and efficacy. &lt;Priority investigation item&gt; Thromboembolism</brief_summary>
	<brief_title>Drug Use Investigation for REVOLADE (ITP)</brief_title>
	<detailed_description />
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
	<mesh_term>Purpura, Thrombocytopenic</mesh_term>
	<criteria>Subjects with chronic idiopathic thrombocytopenic purpura</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>